
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences is poised for significant revenue growth with a large market opportunity for its AI-powered ECG diagnostic solutions. The recent approval and expected FDA approval for its first diagnostic algorithm, along with its MyoVista hardware submission, position the company for success. The company's careful expense control and potential for various revenue streams from its MyoVista Insights platform add to its attractive risk/reward profile. However, risks remain, including balance sheet/liquidity, regulatory delays, and execution challenges.
Bears say
HeartSciences is facing financial struggles, with a lower expense beat in Q3 FY26 and a need for additional financing in order to continue its planned commercialization of its AI-ECG software platform after FDA approvals. This may result in dilution for current shareholders, leading to a negative outlook on the stock despite its potential for improving healthcare with its AI-powered medical technology.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares